- Oral presentation
- Open Access
Effect of growth hormone on bone fragility in patients with Prader-Willi syndrome scoliosis
© Nakamura et al; licensee BioMed Central Ltd. 2015
- Published: 19 January 2015
- Bone Mineral Density
- Growth Hormone
- Bone Fragility
- Growth Hormone Treatment
Patients with Prader-Willi syndrome (PWS) is known to have bone fragility. Osteoporosis may be associated with bone fractures and poor surgical outcome for scoliosis. Current growth hormone (GH) treatment offers a viable and safe means to reduce these risks by improving bone density. The purposes of this study were to investigate bone mineral density (BMD) with PWS patients and to verify efficacy of growth hormone (GH) administration for osteoporosis.
We investigated 148 patients (91 male, 57 females) with PWS who examined BMD and followed for at least 2 years at our out-patient clinic. Measurement was taken at the lumbar spine (L2-4). The mean age was 9.35 (2-47) years at initial BMD. Scoliosis was found in 64 PWS patients (GH plus, 45; minus, 19). Mean cobb angle was 30.6 (range 12-88) degrees. There were 84 non-scoliosis patients (GH plus; 51, GH minus; 33). Patients were treated with GH (0.245 mg/kg/week) over a period of 3 to 16 years (mean, 5 years, 11 months). We also evaluated the effect of GH treatment on BMD in 108 patients who underwent BMD testing more than twice (GH plus, 89 patients; GH minus, 19 patients).
Measuring the lumbar BMD before GH treatment and evaluated the prevalence of bone fragility (osteoporosis and osteopenia) in all patients.
Retrospectively evaluating the association between scoliosis and lumbar BMD.
Comparing the BMD between at initial and at final follow-up stage to determine the effect of GH treatment for the increase of BMD.
1). Total lumbar BMD (L2-4) was 0.567 g/cm (Z score -2.12). Fifty (33.8%) patients had osteoporosis (Z score <-2.5) and 41 (27.7%) patients had osteopenia (-1.5< Z score<-2.5). Total 61.5% of patients showed bone fragility (osteoporosis and osteopenia).
2). The scoliosis group was 0.598 g/cm (Z score -2.08) and non-scoliosis group was 0.548 g/cm (Z score -2.27). There were no significant differences between the two Groups (P=0.075).
3). GH treatment revealed a significant increase of L2-4 BMD (GH plus; 7.95%VS GH minus: 2.57%, P<0.01).
1) 61.5 % of patients with PWS had bone fragility. 2) The frequency of scoliosis was not correlated with BMD.3) GH administration significantly improved BMD. GH therapy may be a useful treatment for reducing the frequency of bone fractures and surgical risk in PWS patients associated with osteoporosis.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.